We used this methodology in Kenya (Dhadphale *et al*, 1983). The SRQ was locally validated and a 7/8 cut-off point was used. Our Department of Psychiatry has now adopted this methodology as a standard procedure for screening psychiatric morbidity in various settings; for example a traditional healer's clinic, during a follow-up study of post-natal women, and in infertility studies. By July 1987, five major epidemiological studies were planned and successfully completed by our postgraduate psychiatric students for their dissertations for the Masters degree in psychiatry.

Although we are generally happy and satisfied with this two-stage methodology, some of the shortcomings of the procedure are: (a) we find only 11 questions of clinical significance; (b) psychotic questions (21 and 23) are too vague and equivocal, especially in our local cultural setting; and (c) inclusion of the brief MAST is important, as both the SRQ and CIS do not appear to be very sensitive instruments for picking up alcohol-related psychiatric disorders. Hence, we have appended the brief MAST to our research protocol.

In a paper based on our extensive experience in East Africa (in preparation), we have discussed these and other parts more critically. We have also translated our research instruments in Kiswahili and other languages.

MANOHAR DHADPHALE

Department of Psychiatry
University of Nairobi
PO Box 30588
Nairobi
Kenya

LESLEY CARTWRIGHT TAYLOR

Ciba-Geigy Regional Medical Centre
PO Box 46057, Nairobi

Khat-Induced Paranoid Psychosis

SIR: Gough & Cookson (*Journal*, February 1988, **152,** 294) mentioned that in our description of the patient F. K. with khat-induced paranoid psychosis (*Journal*, February 1987, **150,** 247–249), the urine test was not in keeping with the diagnosis, because it was positive for morphine and dihydrocodeine but not for amphetamines.

We were not able to explain the presence of morphine and dihydrocodeine in the sample, as we mentioned in the original description. We also stated that the urine sample in question was taken nine days post-admission, at which stage breakdown products of khat, which might have registered a postitive test for amphetamine-like substances (depending on the specificity of the actual test used) would no longer have been present in the urine. In this case the diagnosis was made on clinical grounds and was confirmed by the patient bringing in the khat that she had been using, which was then identified by the Regional Poisons Laboratory.

S. CRITCHLOW
R. SEIFERT

St Bartholomew's Hospital
West Smithfield
London EC1A 7BE

Down's Syndrome with Mania

SIR: Singh (*Journal*, March 1988, **152,** 436–437) responded to our previous case report (*Journal*, February 1987, **150,** 249–250) of DSM–III-diagnosed mania in a young adult with Down's syndrome with several points which we believe require further discussion.

Firstly, our report did not claim that the case was severe enough to require seclusion. However, it is our understanding that 'seclusion' has never been one of the diagnostic criteria for mania. That notwithstanding, the reported case meets the criteria for mania. However, we would hasten to add that developmental considerations *per se* might modify the clinical presentation of mania, and particularly the necessity for seclusion or other means of physical restraint.

Secondly, our discussion of Prange's hypothesis was not meant to suggest a heightened association of Down's syndrome with mania in the absence of clinical data. To the contrary, the intention of that discussion was to highlight the current lack of support for an association, in either direction, between any mental disorder and any physical disorder on the basis of current knowledge of neurochemistry.

Most importantly, Dr Singh presented the literature pertaining to catecholamines by writing that "post-mortem studies of the brains of patients with Down's syndrome clearly show the cell loss in the noradrenergic system of locus coeruleus and dorsal motor vagus, not only in the middle-aged, but also in younger patients." Careful review of the cited references reveals that only two Down's syndrome patients below the age of 48 had been studied: Yates *et al* (1983) found a decrease in hypothalamic but not caudate norepinephrine in one 27-year-old Down's syndrome patient, and Mann *et al* (1985) found decreased cell count in the locus coeruleus but not dorsal motor vagus in the brain of a 31-year-old patient with Down's syndrome. Thus, these are limited studies which do not lend themselves to the broad conclusions suggested by Singh.

Indeed, the study of affective disorders in patients with Down's syndrome may clarify relationships